Last checked at 
LONDON (Alliance News) - AstraZeneca PLC Monday announced collaborations with Incyte Corp and Moderna Therapeutics Inc in cancer treatments.
AstraZeneca will work with Incyte on a phase I/II study, to be conducted by Incyte, of a combination of Incyte's INCB39110 with AstraZeneca's osimertinib, with the phase I part of the trial intended to establish a recommended dose schedule, and the phase II part to assess the safety and efficacy profile of the treatment.
"We are pleased to be building on our existing relationship with Incyte and exploring a potentially exciting combination for lung cancer patients who have developed a resistance to first generation epidermal growth factor receptor inhibitor treatment," said Antoine Yver, head of oncology, Global Medicines Development at AstraZeneca.
The FTSE 100-listed drug maker will work with Moderna Therapeutics in a collaboration to discover, co-develop and co-commercialise candidates for the treatment of a range of cancers, building on an existing agreement between the two to development treatments for cardiovascular, metabolic and renal diseases, as well as selected targets in oncology.
Shares in AstraZeneca were down 0.4% at 4,333.00 pence Monday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
